

MedTech innovation for newborns – Bilihome launches crowdinvesting on Invesdor.de**No more separation: Wearable phototherapy revolutionizes jaundice treatment in newborns / Europe-wide expansion planned**

Berlin/Nijkerk, 6 June 2025 – Every year, millions of parents around the world experience the stressful experience of having to separate their newborn from them due to jaundice treatment. If left untreated, severe jaundice can lead to neurological damage. Bilihome is revolutionizing the treatment of neonatal jaundice with its innovative portable phototherapy solution. Parents and babies can stay together for the first time while the child receives hospital-quality treatment – without incubators, stress and isolation. In order to quickly establish the groundbreaking solution of wearable phototherapy in a soft romper made of organic cotton in Europe, Bilihome is now launching an equity crowdinvesting round on the impact investment platform Invesdor (www.invesdor.de).



At the heart of the innovation, "Jauni Wearable Phototherapy", is a clinically validated, CE-certified romper made of soft organic cotton. This unique medical device enables treatment in the arms of the parents, significantly reduces anxiety and stress, and sustainably strengthens the bond between parents and newborns.

Press contact:

Billihome B.V.:
m.huenerbein@bilihome.com

Invesdor:

Press and Public Relations
Christiane Sternberger
press@invesdor.com
Phone: +49 (0)30 364 285 707

From personal experience to global solution

The founding idea arose from personal concern: **Rick Wielens**, **Co-founder & Head of Operations Bilihome**, had to experience the painful separation from his newborn son during his jaundice treatment. This experience gave rise to the mission to spare families such stressful situations in the future. With Margret Huenerbein, an experienced MedTech expert, Bilihome has been able to gain a strong executive since 2020, who professionally put the company on a growth course and convinced important investors as well as competent partners.



Strong market potential and international growth

Jaundice affects around 14 million newborns worldwide annually, with an addressable global market volume of around 6 billion euros. Bilihome will start commercial launch in 2025, initially in the Netherlands, followed by Germany and Scandinavia in 2026. Collaborations with renowned clinics and hospitals already exist, and further strategic partnerships are planned in Europe, the Middle East, Asia and the USA.

Investment opportunity with impact and return

Until July 17, 2025, private and institutional investors can participate in Invesdor from a minimum investment of 108 shares (per share: €2.32). The offer comprises 1 to 2% of the company's shares with a pre-money valuation of around EUR 8 million. Institutional investors such as Health Innovations, Oost NL and NLC are investing on the same terms, underlining the confidence in Bilihome's growth opportunities. A clear exit strategy within five years aims for a potential return on investment of four to five times.

Use of the funds raised:

- European expansion and establishment of local sales structures
- Clinical Implementation and Customer Support

Press contact:

Bilihome B.V.:
m.huenerbein@bilihome.com

Invesdor:

Press and Public Relations
Christiane Sternberger
press@invesdor.com
Phone: +49 (0)30 364 285 707

- Completion of CE certification (class IIa)
- Product finalization and further development of digital services

Enormous social benefits

Bilihome is finally making family-centered newborn care a reality. Wearable phototherapy can significantly reduce hospital stays, relieve the burden on nursing staff and reduce costs by up to 70%. Just switching just 20% of treatments to the Bilihome solution could provide about 850,000 families a year with stress-free, bond-enhancing treatment.



"We want to make jaundice treatment for newborns more human and emotional. No child should be separated from their parents for medical treatment. With the capital from the current financing, we can now realize this dream throughout Europe and give families worldwide the best possible start in life." (**Margret Huenerbein, CEO & Co-Founder Bilihome**)

About Bilihome: Founded in 2019, Bilihome B.V. develops innovative, wearable solutions for the treatment of neonatal jaundice. The patented product "Jauni Wearable Phototherapy" is about to receive CE certification Class IIa and is already in demand internationally by hospitals. The company is headquartered in Nijkerk, the Netherlands.

About Invesdor: Invesdor is Europe's leading platform for sustainable crowdfounding projects, connecting visionary companies with impact-oriented investors.

Press contact:

Bilihome B.V.:
m.huenerbein@bilihome.com

Invesdor:
Press and Public Relations
Christiane Sternberger
press@invesdor.com
Phone: +49 (0)30 364 285 707